Boundless Bio Statistics
Total Valuation
Boundless Bio has a market cap or net worth of $32.12 million. The enterprise value is -$12.44 million.
| Market Cap | 32.12M |
| Enterprise Value | -12.44M |
Important Dates
The next estimated earnings date is Tuesday, August 4, 2026, before market open.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Boundless Bio has 22.46 million shares outstanding. The number of shares has increased by 0.64% in one year.
| Current Share Class | 22.46M |
| Shares Outstanding | 22.46M |
| Shares Change (YoY) | +0.64% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 1.71% |
| Owned by Institutions (%) | 36.95% |
| Float | 16.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.37 |
| P/TBV Ratio | 0.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.87, with a Debt / Equity ratio of 0.56.
| Current Ratio | 9.87 |
| Quick Ratio | 9.69 |
| Debt / Equity | 0.56 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -50.22% and return on invested capital (ROIC) is -23.72%.
| Return on Equity (ROE) | -50.22% |
| Return on Assets (ROA) | -22.83% |
| Return on Invested Capital (ROIC) | -23.72% |
| Return on Capital Employed (ROCE) | -46.19% |
| Weighted Average Cost of Capital (WACC) | 3.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.00M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +36.19% in the last 52 weeks. The beta is 0.97, so Boundless Bio's price volatility has been similar to the market average.
| Beta (5Y) | 0.97 |
| 52-Week Price Change | +36.19% |
| 50-Day Moving Average | 1.46 |
| 200-Day Moving Average | 1.27 |
| Relative Strength Index (RSI) | 50.24 |
| Average Volume (20 Days) | 66,503 |
Short Selling Information
The latest short interest is 6,060, so 0.03% of the outstanding shares have been sold short.
| Short Interest | 6,060 |
| Short Previous Month | 25,990 |
| Short % of Shares Out | 0.03% |
| Short % of Float | 0.04% |
| Short Ratio (days to cover) | 0.05 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -60.69M |
| Pretax Income | -55.99M |
| Net Income | -55.99M |
| EBITDA | -59.47M |
| EBIT | -60.69M |
| Earnings Per Share (EPS) | -$2.50 |
Balance Sheet
The company has $92.85 million in cash and $48.29 million in debt, with a net cash position of $44.56 million or $1.98 per share.
| Cash & Cash Equivalents | 92.85M |
| Total Debt | 48.29M |
| Net Cash | 44.56M |
| Net Cash Per Share | $1.98 |
| Equity (Book Value) | 86.38M |
| Book Value Per Share | 3.86 |
| Working Capital | 85.03M |
Cash Flow
In the last 12 months, operating cash flow was -$47.10 million and capital expenditures -$495,000, giving a free cash flow of -$47.60 million.
| Operating Cash Flow | -47.10M |
| Capital Expenditures | -495,000 |
| Depreciation & Amortization | 1.22M |
| Net Borrowing | n/a |
| Free Cash Flow | -47.60M |
| FCF Per Share | -$2.12 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Boundless Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.64% |
| Shareholder Yield | -0.64% |
| Earnings Yield | -174.32% |
| FCF Yield | -148.18% |
Analyst Forecast
The average price target for Boundless Bio is $4.00, which is 179.72% higher than the current price. The consensus rating is "Hold".
| Price Target | $4.00 |
| Price Target Difference | 179.72% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |